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ABSTRACT 
Serotonin N-acetyltransferase 
(AANAT) converts serotonin to N-
acetylserotonin (NAS), a distinct biological 
regulator and the immediate precursor of 
melatonin, a circulating hormone that 
influences circadian processes, including 
sleep. N-terminal sequences of AANAT 
enzymes vary among vertebrates. 
Mechanisms that regulate the levels of 
AANAT are incompletely understood. 
Previous findings were consistent with the 
possibility that AANAT may be controlled 
through its degradation by the N-end rule 
pathway. By expressing the rat and 
human AANATs and their mutants not 
only in mammalian cells but also in the 
yeast Saccharomyces cerevisiae, and by 
taking advantage of yeast genetics, we 
show here that two “complementary” 
forms of rat AANAT are targeted for 
degradation by two “complementary” 
branches of the N-end rule pathway. 
Specifically, the Nα-terminally acetylated 
(Nt-acetylated) Ac-AANAT is destroyed 
through the recognition of its 
Nt-acetylated N-terminal Met residue by 
the Ac/N-end rule pathway, whereas the 
non-Nt-acetylated AANAT is targeted by 
the Arg/N-end rule pathway, which 
recognizes the unacetylated N-terminal 
Met-Leu sequence of rat AANAT. We also 
show, by constructing lysine-to-arginine 
mutants of rat AANAT, that its 
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degradation is mediated by 
polyubiquitylation of its Lys residue(s). 
Human AANAT, whose N-terminal 
sequence differs from that of rodent 
AANATs, is longer-lived than its rat 
counterpart, and appears to be refractory 
to degradation by the N-end rule pathway. 
Together, these and related results 
indicate both a major involvement of the 
N-end rule pathway in the control of 
rodent AANATs and substantial 
differences in the regulation of rodent and 
human AANATs that stem from 
differences in their N-terminal sequences. 
 
Arylalkylamine N-acetyltransferase 
(AANAT) converts the neurotransmitter 
serotonin to N-acetylserotonin (NAS) (1-11). 
Regulatory functions of NAS include its 
activity as an agonist of TrkB, the receptor 
for the brain-derived neurotrophic factor 
(BDNF) (12-14). NAS is the immediate 
precursor of melatonin, a circulating 
hormone that regulates sleep and other 
circadian processes in vertebrates. Melatonin 
is also present in invertebrates, including 
insects, as well as in animals that lack 
recognizable neurons (1,15-21). The 
functions of melatonin in mammals include 
the modulation of circadian rhythms in 
response to light-dark cycles. Melatonin also 
contributes to the control of seasonal 
physiology (20). These mechanisms are a 
part of a broader range of processes that 
involve distinct biological oscillators in all 
organisms (22-24). In the course of daily 
light-dark cycles, the activity of AANAT and 
the level of the ~23-kDa AANAT protein in 
the brain’s pineal gland are high during 
nocturnal periods and rapidly decrease 
following exposure to light (1,20,25). 
In mammals, changes of AANAT 
levels in the brain’s pineal gland are 
controlled by the circadian oscillator in the 
suprachiasmatic nucleus (SCN) of the 
hypothalamus. At night, axons of rodent 
superior cervical ganglion neurons release 
norepinephrine (NE) in the pineal gland, in 
response to circadian signals from the SCN, 
thereby activating adrenergic receptors to 
increase intracellular Ca2+ and cAMP. The 
resulting phosphorylation of CREB, the 
cAMP response element (CRE)-binding 
protein, upregulates the Aanat transcriptional 
promoter, which contains CRE sequence 
elements (1,4,25-27). Increases in cAMP also 
stimulate the site-specific phosphorylation of 
AANAT by the protein kinase A (PKA), 
thereby causing the binding of AANAT to 
14-3-3 proteins. These transitions augment 
the enzymatic activity of AANAT and inhibit 
its degradation (1,6,7,28). While AANAT is 
predominantly expressed in the pineal gland 
and the retina, this enzyme is also present in 
cells of the gastrointestinal tract, and 
apparently at other sites as well, including 
the hippocampus, the olfactory bulb, the 
cerebellum, and the spinal cord (12,29,30). 
Melatonin is produced from NAS by 
hydroxyindole-O-methyltransferase 
(HIOMT). The levels of NAS, synthesized 
by AANAT, can constrain the rate of 
melatonin synthesis from NAS during light 
parts of daily cycles (when NAS levels are 
low) but appear to be not the rate-limiting 
step during dark parts of these cycles, when 
both AANAT and NAS levels are high (21). 
In rodents such as rats the activity of 
AANAT starts to increase 3 to 4 h after the 
onset of darkness and begins to decrease 
before the onset of light in the morning 
(21,31). Hence the importance of regulating 
the expression and the enzymatic activity of 
AANAT, as these parameters determine the 
levels of both NAS and melatonin. 
The concentration of AANAT, a 
largely cytosolic enzyme (32), is controlled 
through both transcriptional and 
posttranslational mechanisms (1,11,31,33-
35). In rodents, the onset of darkness leads to 
an increase in melatonin (requiring a 
preceding increase of NAS) after a lag 
period, whereas in sheep and primates 
increases in melatonin occur rapidly upon the 
onset of darkness. The levels of Aanat 
mRNA in rodents can vary by >100-fold 
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during light-dark cycles (10), whereas in 
non-rodent mammals such as, for example, 
sheep, these differences can be as low as 
~2-fold, suggesting a major involvement of 
translational and/or posttranslational 
AANAT regulation in latter cases (11,36). In 
addition to variability in regulation at the 
level of AANAT-encoding mRNAs, 
AANAT is also unusual in the extent of 
variability of its N-terminal sequences during 
vertebrate evolution (Fig. 1C). In 2010, one 
of our laboratories showed that N-terminal 
residues of rat AANAT play a role in the 
control of its degradation, suggesting the 
involvement of the N-end rule pathway (37). 
The N-end rule pathway is a set of 
intracellular proteolytic systems whose 
unifying feature is the ability to recognize 
and polyubiquitylate proteins containing 
N-terminal degradation signals (degrons) 
called N-degrons, thereby causing 
degradation of these proteins by the 
proteasome (Fig. 1A, B) (38-46). Ubiquitin 
(Ub) ligases of the N-end rule pathway, 
called N-recognins, can recognize not only 
N-degrons but also specific internal 
degradation signals (47-50). The main 
determinant of an N-degron is either an 
unmodified or chemically modified 
destabilizing N-terminal residue of a protein. 
Another determinant of an N-degron is a 
protein’s internal Lys residue(s). It functions 
as the site of polyubiquitylation and tends to 
be located in a conformationally disordered 
region (41,51,52). Bacteria also contain the 
N-end rule pathway, but Ub-independent 
versions of it (53-58). 
Regulated degradation of proteins and 
their natural fragments by the N-end rule 
pathway has been shown to mediate a 
strikingly broad range of biological 
functions, including the sensing of heme, 
nitric oxide (NO), oxygen, and short 
peptides; the control of the input 
stoichiometries of subunits in oligomeric 
protein complexes; the elimination of 
misfolded or otherwise abnormal proteins; 
the degradation of specific proteins after their 
retrotranslocation to the cytosol from 
membrane-enclosed compartments; the 
regulation of apoptosis and repression of 
neurodegeneration; the regulation of DNA 
repair, transcription, replication, and 
chromosome cohesion/segregation; the 
regulation of G proteins and cytoskeletal 
proteins such as actin and myosin; the 
regulation of autophagy, peptide import, 
meiosis, immunity, fat metabolism, cell 
migration, cardiovascular development, 
spermatogenesis, and neurogenesis; the 
functioning of adult organs, including the 
brain, muscle, testis, and pancreas; and the 
regulation of leaf and shoot development, 
leaf senescence, and many other processes in 
plants (Figs. 1A, B) ((41-46) and references 
therein). 
In eukaryotes, the N-end rule 
pathway consists of two branches. One 
branch, called the Ac/N-end rule pathway, 
targets proteins for degradation through their 
Nα-terminally acetylated (Nt-acetylated) 
residues (Fig. 1B) (39,40,46,59-62). 
Degradation signals and E3 Ub ligases of the 
Ac/N-end rule pathway are called 
Ac/N-degrons and Ac/N-recognins, 
respectively. Nt-acetylation of cellular 
proteins is apparently irreversible, in contrast 
to acetylation-deacetylation of proteins’ 
internal Lys residues. About 90% of human 
proteins are cotranslationally Nt-acetylated 
by ribosome-associated Nt-acetylases (63). 
Ac/N-degrons are present in many, possibly 
most, Nt-acetylated proteins (Fig. 1B). 
Natural Ac/N-degrons are regulated through 
their reversible shielding in cognate protein 
complexes (59). 
The pathway’s other branch, called 
the Arg/N-end rule pathway, targets specific 
unacetylated N-terminal residues (Fig. 1A) 
(40,64-68). The “primary” destabilizing 
N-terminal residues Arg, Lys, His, Leu, Phe, 
Tyr, Trp, and Ile are directly recognized by 
N-recognins. The unacetylated N-terminal 
Met, if it is followed by a bulky hydrophobic 
(Ф) residue, also acts as a primary 
destabilizing residue (Fig. 1A) (40). In 
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contrast, the unacetylated N-terminal Asn, 
Gln, Asp, and Glu (as well as Cys, under 
some metabolic conditions) are destabilizing 
owing to their preliminary enzymatic 
modifications, which include N-terminal 
arginylation (Fig. 1A) (41-43,69). In the 
yeast Saccharomyces cerevisiae, the 
Arg/N-end rule pathway is mediated by the 
Ubr1 N-recognin, a 225 kDa RING-type E3 
Ub ligase and a part of the targeting complex 
comprising the Ubr1-Rad6 and Ufd4-Ubc4/5 
E2-E3 holoenzymes (41,70). In multicellular 
eukaryotes, several E3 Ub ligases, including 
Ubr1, function as N-recognins of the 
Arg/N-end rule pathway (Fig. 1A). 
In S. cerevisiae, the Ac/N-end rule 
pathway is mediated by (at least) the 
cytosolic/nuclear E3 Ub ligase Not4 and by 
Doa10, an endoplasmic reticulum (ER) 
membrane-embedded E3 (59). In mammalian 
cells, this pathway is mediated by (at least) 
the Teb4 E3, which is sequelogous (similar 
in sequence (71)) to yeast Doa10 (60). 
Human RGS2, a regulator of specific G 
proteins, is a short-lived substrate of the 
Ac/N-end rule pathway both in mammalian 
cells and in the heterologous setting of S. 
cerevisiae (60,72,73). In addition, the 
naturally occurring (blood pressure-
elevating) human RGS2Q2L mutant (in which 
Gln at position 2 is replaced by Leu) is 
targeted for degradation by both the Ac/N-
end rule pathway and the Arg/N-end rule 
pathway (60). The Ac/N-end rule pathway 
recognizes the Nt-acetylated Ac-RGS2Q2L 
(specifically, its N-terminal Ac-Met residue), 
whereas the non-Nt-acetylated RGS2Q2L is 
targeted (through its N-terminal Met-Leu 
sequence) by the Arg/N-end rule pathway 
(60).  
In the present work, we analyzed the 
proteasome-mediated degradation of rat 
AANAT (37), whose N-terminal sequence 
Met-Leu (Fig. 1C) is identical to that of the 
otherwise unrelated human RGS2Q2L protein 
(60). We also characterized human AANAT, 
which is highly sequelogous (71) (84% 
identical) to rat AANAT but bears a different 
N-terminal sequence (Fig. 1C). Our analyses 
employed the previously helpful approach of 
dissecting degradation of a mammalian 
protein of interest not only in a homologous 
(mammalian) setting but also in S. cerevisiae 
(60,66), thereby making possible the use of 
yeast genetics. 
We show here that two alternative 
versions of rat AANAT, its Nt-acetylated and 
non-Nt-acetylated forms, are targeted for 
degradation by the Ac/N-end rule pathway 
and the Arg/N-end rule pathway, 
respectively. In contrast, human AANAT, 
whose N-terminal sequence differs from that 
of rodent AANATs, is significantly 
longer-lived than its rat counterpart, and 
appears to be largely refractory to 
degradation by the N-end rule pathway. 
Together, these and related results indicate 
both a major involvement of the N-end rule 
pathway in the control of rodent AANATs 
and substantial differences in the regulation 
of rodent and human AANATs that stem 
from differences in their N-terminal 
sequences.  
 
Experimental Procedures 
Yeast Strains, Media, and Genetic 
Techniques – Standard yeast genetic 
techniques were used (74-76). S. cerevisiae 
strain BWY29 was constructed by 
transforming the strain CHY345 
(ubr1∆::LEU2 in the strain background of 
BY4742) with a PCR-amplified DNA 
fragment that encoded the selection marker 
KanMX6 (making cells resistant to 
kanamycin) and was targeted to the 5’ and 3’ 
flanking regions of the NAA10 gene, thereby 
replacing the open reading frame (ORF) of 
NAA10 with KanMX6 (Table 1). S. cerevisiae 
strain JOY487 was made by transforming 
BY4742 with a PCR-amplified DNA 
fragment that encoded the natNT2 marker 
(making cells resistant to nourseothricin) and 
was targeted to the 5’ and 3’ flanking regions 
of PDR5, thereby replacing the ORF of 
PDR5 with natNT2 (Table 1). The resulting 
pdr5∆ cells were used in experiments that 
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involved the MG132 proteasome inhibitor 
(Fig.4A, B). Other S. cerevisiae strains used 
in this study were constructed previously and 
are cited in Table 1. S. cerevisiae were 
transformed using the LiAc/PEG method 
(77). S. cerevisiae media included YPD 
medium, synthetic complete (SC) medium, 
and synthetic drop-out (SD) medium (75,76). 
Plasmids, cDNAs, and Primers – 
NEB Turbo Escherichia coli (New England 
Biolabs (NEB), Ipswich, MA) was used for 
cloning and maintaining plasmids. Phusion 
High-Fidelity DNA polymerase (NEB) was 
used for carrying out PCR. Nucleotide 
sequences of all plasmids were verified by 
DNA sequencing. The plasmids and PCR 
primers used in this study are described in 
Tables 2 and 3, respectively. 
The low copy pBW105, pBW106, 
pBW107, and pBW209 plasmids expressed 
respectively, the wild-type rat MLSrAANAT3f 
(wild-type rat AANAT bearing the N-
terminal sequence Met-Leu-Ser and 
C-terminally tagged with a triple-FLAG 
epitope) and its N-terminal mutants 
(M)SIrAANAT3f, 
(M)SMLSrAANAT3f, and 
(M)PLSrAANAT3f from the PGAL1 promoter. To 
construct these plasmids, the rat Aanat ORF 
was amplified from pCISII-rAANAT (78), 
using primers BW2394, BW240, BW241, 
BW412, BW243, and BW244 (Table 3). The 
resulting PCR products were digested with 
EcoRI and HindIII, and cloned in 
EcoRI/HindIII-cut pRS416GAL1. 
The low copy pBW135 and pBW394 
plasmids expressed, respectively, the 
wild-type rat MLSrAANAT C-terminally 
tagged with the triple-HA epitope 
(MLSrAANAT3ha) and its Lys-8-to-Arg-8 
mutant MLSrAANAAT3ha
K8R from the PCUP1 
promoter. To construct these plasmids, the 
rat Aanat ORF was amplified from 
pCISII-rAANAT (78) using primers BW339, 
BW704, BW338, BW339, BW340 (Table 3). 
The amplified DNA fragments were digested 
with EcoRI and XhoI, and cloned in 
EcoRI/XhoI-cut pRS313CUP1 (59,79).  
The low copy pBW395 and pBW419 
plasmids expressed, respectively, the 
wild-type human (M)SThAANAT C-terminally 
tagged with a triple-FLAG epitope 
((M)SThAANAT3f) and its N-terminal mutant 
(M)PThAANAT3f from the PGAL1 promoter. To 
construct these plasmids, the human AANAT 
ORF from Genscript Clone #OHu55705 
(Genscript, Piscataway, NJ) was amplified 
using primers BW705, BW711, BW712, and 
BW244, or primers BW771, BW711, 
BW712, and BW244, respectively (Table 3). 
The PCR-amplified DNA fragments were 
digested with EcoRI and HindIII, and were 
ligated into EcoRI/HindIII-cut pRS416GAL1 
(79). All final DNA constructs were verified 
by DNA sequencing. See items i-x at the 
beginning of Results for information about 
rat and human AANAT notations. 
For expression of the above AANAT-
encoding ORFs in human HEK293T cells, 
these ORFs were cloned into a modified 
expression vector derived from pcDNA3. 
That (modified) vector, termed 
pcDNA3CMVt1, contained a truncated 
(weakened) version of the PCMV promoter, 
termed PCMVt1. The pcDNA3CMVt1 plasmid 
was constructed by amplifying, using PCR, 
the 276-base pairs (bp) fragment that 
encompassed 104 bp at the 3’ end of the 
PCMV promoter region in pcDNA3, its T7 
promoter site, and its multiple cloning site, 
using primers BW375 and BW376 (Table 3). 
The amplified DNA fragment was digested 
with NruI and XbaI and ligated into 
NruI/XbaI-cut pcDNA3, yielding the plasmid 
pBW173 (Table 2). Its truncated PCMVt1 
promoter retained several proximal promoter 
elements, including the consensus NFkB site, 
the CREB-binding site, and two SP1/SP3-
binding sites, but lacked more distal 
enhancer elements. This resulted in a ~70% 
lower activity of the PCMVt1 promoter in 
HEK293T cells, in comparison to PCMV (Fig. 
5A-C). 
The pcDNA3CMVt1-based plasmids 
pBW206, pBW211, pBW212, and pBW213 
expressed, in HEK293T cells, either the 
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wild-type rat MLSrAANAT3f or its N-terminal 
mutants (M)SIrAANAT3f, 
(M)SMLSrAANAT3f, 
and (M)PLSrAANAT3f from the PCMVt1 
promoter. To construct these plasmids, Aanat 
ORFs were amplified from the plasmids 
pBW105, pBW106, pBW107, and pBW209 
using primers BW352, BW353, BW354, 
BW413, and BW355, respectively (Table 3). 
The amplified DNA fragments were digested 
with EcoRI and XhoI, and ligated in 
EcoRI/XhoI-cut pBW173 (Table 2). All 
pcDNA3-based constructs designed for 
expression in HEK293T cells contained the 
Kozak sequence 5’-ACC immediately 
upstream of the start codon. 
pBW477, which expressed the 
MLSrAANAT3ha from the PCMVt1 promoter, 
was constructed by using pBW135 as a PCR 
template and the primers BW352/BW340. 
The resulting PCR-amplified DNA fragment 
was digested with EcoRI and XhoI, and 
ligated into EcoRI/XhoI-cut pBW173 (Table 
2). pBW478 expressed MLSrAANAAT3ha
Kzero, 
i.e., the lysine-lacking derivative of 
MLSrAANAT3ha. It was constructed by using 
pBW135 as a PCR template to generate four 
separate DNA fragments containing lysine-
to-arginine mutations. The primer pairs were 
704/784, 785/786, 787/788, and 789/340 
(Table 3). These fragments were then 
assembled into a contiguous ORF using 
PCR. The resulting DNA fragment, encoding 
lysine-to-arginine mutations at each of the 
four lysines contained in the wild-type rat 
MLSrAANAT3f, was digested with EcoRI and 
XhoI, and ligated into EcoRI/XhoI-cut 
pBW173. 
pBW466 and pBW467, the pcDNA3-
based counterparts of pBW395 and pBW419 
(Table 2) were generated by PCR using 
pBW395 and pBW419 as templates, and the 
primers BW866/BW355 and 
BW868/BW355, respectively (Table 3). 
PCR-amplified DNA fragments were 
digested with EcoRI and XhoI and ligated 
into EcoRI/XhoI-cut pBW173 (Table 2). 
Cell Culture – The HEK293T cell 
line (derived from human embryonic kidney 
cells) was obtained from American Type 
Culture Collection (ATCC, Manassas, VA), 
and was grown at 37°C in 5% CO2 in 
Dulbecco’s Modified Eagle Medium 
(DMEM) medium supplemented with 10% 
fetal bovine serum (FBS) (Gemini Bio-
Products, West Sacramento, CA) and 
penicillin/streptomycin (100 units/ml; 
Hyclone). Cells were transfected using 
Lipofectamine-2000 (Invitrogen) according 
to the manufacturer’s protocol. 
Antibody Specific for the Nt-
acetylated Form of Rat AANAT (MLSrAANAT) 
– Unpurified rabbit polyclonal antisera 
against the synthetic peptide 
Ac-MLSIHPLKPEAC were produced by 
Abgent (San Diego, CA) essentially as 
described for other peptide-mediated 
polyclonal antibodies produced in studies by 
the Varshavsky laboratory (e.g., (59,66)). 
The sequence of the Nt-acetylated peptide 
immunogen comprised the first 11 residues 
of MLSrAANAT (Fig. 1C and below), 
followed by the C-terminal Cys residue that 
was used to conjugate the peptide to keyhole 
limpet hemocyanin (KLH) carrier protein. 
The antiserum was affinity-purified in two 
sequential steps. First, the antibody sample 
was incubated with the C-terminally 
immobilized original immunogen Ac-
MLSIHPLKPEAC. The peptide-bound 
fraction was eluted as previously described 
(59,66). That fraction was thereafter 
“negatively” purified against the otherwise 
identical but non-Nt-acetylated immobilized 
MLSIHPLKPEAC peptide (the peptides 
were immobilized using a sulfhydryl-
coupling resin (Abgent)), collecting, this 
time, the unbound fraction. The resulting 
antibody sample was used to detect, 
selectively, the Nt-acetylated form of rat 
AANAT (see Results and Fig. 5D). The 
fraction of once-purified antibody that was 
bound to the non-Nt-acetylated 
MLSIHPLKPEAC peptide was also eluted 
and retained, and was used as an antibody 
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that could recognize the N-terminal region of 
rat AANAT irrespective of its Nt-acetylation 
state. 
Cycloheximide Chase Assay in S. 
cerevisiae – Cycloheximide (CHX) chase 
assays in S. cerevisiae were performed 
largely as described (39,59). Briefly, S. 
cerevisiae cells were grown in overnight 
cultures, and expression of epitope-tagged 
test proteins was induced by the addition of 
2% galactose (for plasmids containing the 
PGAL1 promoter) or 0.1 mM CuSO4 (for 
plasmids containing the PCUP1 promoter 
(80)). 3 h post-induction, CHX was added to 
the final concentration of 0.1 mg/ml. 
Samples were collected at the indicated time 
points, centrifuged at 11,200g for 2 min to 
pellet the cells, and snap-frozen in liquid 
nitrogen. Proteins were extracted by 
resuspending the pellets in 1 ml of 0.2 M 
NaOH and incubating on ice for 20 min (81). 
Cells were then pelleted and resuspended in 
50 μl of SUMEB loading buffer (1% SDS, 8 
M urea, 10 mM EDTA, 0.01% bromophenol 
blue, 10 mM MOPS, pH 6.8), followed by 
heating at 95°C for 10 min. Samples were 
then centrifuged at 11,200g for 5 min, 
followed by the SDS-PAGE (with 10 μl 
loaded per well) using 4-12% NuPAGE gels 
(Invitrogen). Fractionated proteins were 
transferred onto nitrocellulose membranes 
for immunoblotting analyses (see below).  
Cycloheximide Chase Assay in 
Mammalian Cell Lines – HEK293T cells 
were transfected with 4 μg of plasmid DNA 
per well (10 cm2 surface area) in 6-well 
plates using Lipofectamine-2000 (Invitrogen) 
according to the manufacturer’s protocol. 24 
h after transfection cells were treated with 
cycloheximide (CHX; 0.1 mg/ml) to initiate 
a chase. All cells from one well were 
collected at each indicated time-point by 
washing cells quickly in ice-cold phosphate-
buffered saline (PBS), then rapidly scraping 
cells into 1.5 ml tubes, pelleting them by 
centrifugation at 4°C (at 10,000g for 1 min), 
and snap-freezing the pellets in liquid 
nitrogen. Cells in these samples were later 
lysed by the addition of 0.2 ml of 
“mammalian lysis buffer” (1% NP40, 0.15 M 
NaCl, 50 mM Tris-HCl, pH 7.5) containing 
1x Roche Complete Protease Inhibitor 
Cocktail, and brief sonication, followed by 
centrifugation at 11,200g for 10 min. Total 
protein concentration in the supernatants was 
measured by the bicinchoninic acid (BCA) 
assay (Thermo Fisher Scientific, Waltham, 
MA). 30 μg of total protein in a thus 
prepared extract in lithium dodecyl sulfate 
(LDS)-sample buffer (in the volume of 45 μl) 
were heated at 70°C for 10 min, followed by 
LDS-PAGE on a 4-12% Bis-Tris NuPAGE 
gel (Invitrogen), and subsequent transfer onto 
nitrocellulose membranes for 
immunoblotting.  
Immunoblotting – Following 
electrophoresis, proteins separated by 
LDS-PAGE or SDS-PAGE, as indicated 
above, were electroblotted on nitrocellulose 
membranes by iBlot (Invitrogen, Carlsbad, 
CA; Program 3; 7 min transfer). Membranes 
were blocked and thereafter incubated with 
the appropriate primary antibody, followed 
by LI-COR IRDye-conjugated secondary 
antibodies. IRDye fluorescence was detected 
using LI-COR Odyssey 9120 (LI-COR, 
Lincoln, NE), facilitating quantification of 
immunoblots. All quantification was done on 
LI-COR Odyssey software. Antibodies used 
include: anti-FLAG mouse monoclonal 
antibody (clone M2; 1:2,000 dilution; Sigma-
Aldrich, St. Louis, MO), anti-α-tubulin 
mouse monoclonal antibody (clone B-5-1-2; 
1:10,000 dilution; Sigma-Aldrich), anti-HA 
mouse monoclonal antibody (clone HA-7; 
1:2000 dilution; Sigma-Aldrich), anti-β-actin 
mouse monoclonal antibody Ab8224 
(Abcam, 1:4,000 dilution; Cambridge, UK), 
and anti-14-3-3ζ rabbit monoclonal antibody 
EPR6379 (1:100,000 dilution; Abcam).  
Immunoprecipitation of 
Polyubiquitylated AANAT – HEK293T cells 
were transfected with 4 μg of plasmid DNA 
per well (10 cm2 surface area) in 6-well 
plates using Lipofectamine-2000 (Invitrogen) 
according to the manufacturer’s protocol. 24 
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h after transfection, cells were treated with 
the proteasome inhibitor MG132 (final 
concentration of 10 μM; AG Scientific, San 
Diego, CA), or with an equivalent volume of 
dimethylsulfoxide (DMSO) in which the 10 
mM stock solution of MG132 was made, as 
indicated. 6 h post-treatment cells were 
collected by washing them quickly on a plate 
in ice-cold phosphate-buffered saline (PBS), 
then rapidly scraping cells into 1.5 ml tubes 
and pelleting them by centrifugation at 4°C 
at 10,000g for 1 min). Pellets were 
resuspended in 0.1 ml of buffer containing 
1% SDS and 50 mM Tris (pH 7.5), and 
heated at 95°C for 10 min. After boiling, 
samples were diluted with 1 ml of buffer 
TNN (0.5% NP40, 0.25 M NaCl, 5 mM 
EDTA, 50 mM Tris, pH 7.5) containing 
1x Roche Complete Protease Inhibitor 
Cocktail, 20 mM N-ethylmaleimide (NEM, 
Sigma-Aldrich) and 50 μM PR-619 
(LifeSensors, Malvern, PA) as inhibitors of 
deubiquitylation. 25 μl of anti-HA magnetic 
beads were then added to each sample, which 
were incubated at 4°C overnight, followed by 
3 washes in TNN, 1 wash in 10 mM Tris-
HCl, pH 8.5, and elution with 50 μl 0.1 M 
glycine, pH 2.0 by incubation at room 
temperature for 10 min. After elution, the 
samples were neutralized, then heated at 
70°C in LDS-PAGE sample buffer, followed 
by LDS-PAGE on a 4-12% NuPAGE gel. 
Fractionated proteins were then 
electroblotted onto nitrocellulose 
membranes. The resulting membranes 
(containing transferred proteins) were 
autoclaved as previously described (82) prior 
to “downstream” immunoblotting procedures 
with either anti-HA or anti-ubiquitin 
antibodies to increase the sensitivity of 
detection of polyubiquitin chains. 
 
Results 
 
Wild-type Rat and Human AANATs 
and their Mutants – The start (AUG) 
codon-encoded N-terminal Met residue of 
nascent proteins is cotranslationally cleaved 
off by ribosome-associated 
Met-aminopeptidases (MetAPs) if a residue 
at position 2, to be made N-terminal by the 
cleavage, is not larger than Val (41,83). 
Thus, for example, the Met residue of the 
N-terminal Met-Leu-Ser sequence of wild-
type rat AANAT (denoted as MLSrAANAT) 
(Fig. 1C) is retained in mature MLSrAANAT, 
inasmuch as Leu is larger than Val. Given the 
previously demonstrated usefulness of 
employing genetic tractability of S. 
cerevisiae for understanding the targeting of 
mammalian N-end rule substrates (60,66), 
we carried out the present study by 
expressing AANAT test proteins not only in 
human HEK293T cells but also in S. 
cerevisiae. Cited below are the examined 
wild-type and mutant AANAT proteins. 
When present, parentheses around a 
superscript’s N-terminal Met residue in the 
notations of AANAT test proteins denote the 
fact that this Met is cotranslationally cleaved 
off by MetAPs. 
(i) MLSrAANAT3f, the wild-type rat 
MLSrAANAT C-terminally tagged with a 
triple-FLAG epitope (Figs. 1C and 2A). 
(ii) (M)SMLSrAANAT3f, in which the 
sequence (Met)-Ser was placed before the 
wild-type Met-Leu-Ser sequence of rat 
MLSrAANAT3f, yielding the N-terminal 
sequence (Met)-Ser-Met-Leu-Ser. Its 
N-terminal Met residue would be 
cotranslationally cleaved off by MetAPs 
(Fig. 2A). The (Met)-Ser sequence was 
added to wild-type MLSrAANAT3f in order to 
mimic the (Met)-Ser N-terminal sequence of 
primate (including human) AANATs 
(Fig. 1C). 
(iii) (M)SIrAANAT3f, in which Leu at 
position 2 of the wild-type rat MLSrAANAT3f 
(Fig. 1C) was deleted, thereby making the 
N-terminal Met of the resulting 
(M)SIrAANAT3f removable by MetAPs (Figs. 
1C and 2A). 
(iv) (M)PLSrAANAT3f, in which the 
Pro residue was inserted between N-terminal 
Met and second-position Leu of wild-type rat 
MLSrAANAT3f. This alteration aimed to 
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address the relevance of Nt-acetylation to the 
degradation of wild-type rat MLSrAANAT3f. 
Specifically, the N-terminal sequence 
Met-Leu-Ser is a priori likely to be 
cotranslationally Nt-acetylated in vivo at its 
(retained) N-terminal Met (59,62,63). In 
contrast, the N-terminal Met residue of the 
mutant N-terminal sequence (Met)-Pro-Leu-
Ser of (M)PLSrAANAT3f would be 
cotranslationally cleaved off by MetAPs. The 
resulting N-terminal Pro is not Nt-acetylated 
at least in S. cerevisiae, and is usually not 
Nt-acetylated in mammalian cells as well 
(59,63). 
(v) MLSrAANAT3ha, the wild-type rat 
MLSrAANAT (Fig. 1C) C-terminally tagged 
with a triple-HA epitope. It was used as a 
control for the MLSrAANAAT3ha
K8R mutant 
described in item viii. 
(vi) (M)SThAANAT3f, the wild-type 
human (M)SThAANAT (Fig. 1C) C-terminally 
tagged with a triple-FLAG epitope. 
(vii) (M)PThAANAT3f, in which the 
second-position Ser of the wild-type human 
(M)SThAANAT3f (Fig. 1C) was replaced by 
the Pro residue, yielding (M)PThAANAT3f. 
The N-terminal Met residue of either the 
wild-type human (M)SThAANAT3f or the 
mutant (M)PThAANAT3f would be 
cotranslationally removed by MetAPs 
(41,83). However, in contrast to the resulting 
N-terminal Ser of wild-type SThAANAT3f, 
which would be expected to be 
cotranslationally Nt-acetylated, the 
N-terminal Pro of the mutant PThAANAT3f is 
not Nt-acetylated at least in S. cerevisiae, and 
is usually not Nt-acetylated in mammalian 
cells as well (59,63). 
(viii) MLSrAANAAT3ha
K8R, the otherwise 
wild-type triple-HA-tagged rat MLSrAANAT 
in which the Lys-8 residue was replaced by 
Arg. 
(ix) MLSrAANAAT3ha
Kzero, the 
otherwise wild-type triple-HA-tagged rat 
MLSrAANAT in which each of its four Lys 
residues were replaced by Arg (Fig. 6B). 
(x) (M)SThAANAAT3ha
Kzero, the 
otherwise wild-type triple-HA-tagged 
human (M)SThAANAT in which both its Lys 
residues were replaced by Arg (Fig. 7A and 
D). 
Degradation of Rat AANAT by the S. 
cerevisiae N-end Rule Pathway – In 
cycloheximide (CHX) assays, a protein of 
interest is analyzed by immunoblotting as a 
function of time after the inhibition of 
translation by CHX (39,59,60). Both the 
wild-type rat MLSrAANAT3f (Fig. 1C) and its 
(M)SMLSrAANAT3f mutant (see item ii above) 
were rapidly degraded in wild-type S. 
cerevisiae, with half-lives (t1/2) < 5 min 
(Fig. 2B, lanes 3-10, and Fig. 2D). In striking 
contrast, (M)SIrAANAT3f (see item iii above), 
produced from wild-type MLSrAANAT3f by 
deleting the Leu residue at position 2, was 
virtually completely stable under the same 
conditions, with a t1/2 > 1 h (Fig. 2B, lanes 
11-14 and Fig. 2D).  
Since the N-terminal Met residue in 
the Met-Leu-Ser sequence of the wild-type 
rat MLSrAANAT3f would be likely to be 
Nt-acetylated in vivo (59,62,63), the rapid 
degradation of MLSrAANAT3f  (t1/2 < 5 min) 
(Fig. 2B, D) suggested the involvement of 
the Ac/N-end rule pathway (Fig. 1A). To 
address this possibility, we constructed the 
non-Nt-acetylatable (M)PLSrAANAT3f mutant 
(see item iv above). (This mutant would also 
not be expected to be targetable by the 
Arg/N-end rule pathway, as the latter does 
not recognize N-terminal Pro (40,41)). 
Remarkably, (M)PLSrAANAT3f was long-lived 
in S. cerevisiae, in comparison to the short-
lived wild-type MLSrAANAT3f (t1/2 ≈ 1h 
versus t1/2 < 5 min, respectively), strongly 
suggesting (but not proving) a role for the 
Ac/N-end rule pathway in the degradation of 
the wild-type rat MLSrAANAT3f (Fig. 2B, 
lanes 15-18, and Fig. 2D; see also below). 
To further address the involvement of 
the Ac/N-end rule and Arg/N-end rule 
pathways (Fig. 1A, B) in the degradation of 
wild-type MLSrAANAT3f, we performed 
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CHX-chases in S. cerevisiae mutants that 
lacked essential components of either one or 
both of these pathways. The normally short-
lived rat MLSrAANAT3f (t1/2 < 5 min; Fig 2C, 
lanes 2-5, and Fig. 2E) was partially 
stabilized in both naa30Δ and ubr1Δ mutants 
(Fig. 2C, lanes 6-9, lanes 14-17, and Fig. 
2E). S. cerevisiae naa30Δ cells lack the 
cognate NatC Nt-acetylase whose substrates 
include proteins bearing the N-terminal Met-
Leu sequence (59,62,63,84,85). S. cerevisiae 
ubr1Δ cells lack Ubr1, the E3 Ub ligase (N-
recognin) that is essential for the proteolytic 
activity of the Arg/N-end rule pathway (Fig. 
1A) (40,41,59). 
Crucially, the relative stabilization of 
MLSrAANAT3f was dramatically higher in the 
double mutant naa30Δ ubr1Δ than in either 
one of the single mutants (Fig 2C, lanes 
18-21, and Fig.2E). These findings should be 
considered together with the conceptually 
independent result that the 
non-Nt-acetylatable (and also not targetable 
by the Arg/N-end rule pathway) 
(M)PLSrAANAT3f mutant (see the preceding 
paragraph) was much longer-lived in wild-
type S. cerevisiae than its wild-type 
MLSrAANAT3f counterpart (Fig. 2B, lanes 
15-18 vs. lanes 3-6, and Fig. 2D). Together, 
these sets of findings indicated that the 
wild-type rat MLSrAANAT3f (its two 
alternative forms) was targeted for 
degradation by both the Ac/N-end rule 
pathway and the Arg/N-end rule pathway. 
Specifically, the Nt-acetylated 
Ac-MLSrAANAT3f is destroyed through the 
recognition of its Nt-acetylated N-terminal 
Met residue by the Ac/N-end rule pathway 
(Fig. 1B), while the non-Nt-acetylated 
MLSrAANAT3f is targeted by the 
“complementary” Arg/N-end rule pathway, 
which recognizes the unacetylated 
N-terminal Met-Leu sequence of 
MLSrAANAT3f as the Met-Ф motif 
(N-terminal Met followed by a bulky 
hydrophobic residue) (Fig 1A). 
This conclusion was in agreement 
with the finding that the rapid degradation of 
MLSrAANAT3f in wild-type S. cerevisiae (t1/2 
< 5 min) remained unchanged in naa10Δ 
cells, which lacked the non-cognate NatA 
Nt-acetylase (which does not Nt-acetylate N-
terminal Met) (59,85). Furthermore and also 
in agreement with the above conclusion, the 
degradation of MLSrAANAT3f in double-
mutant naa10Δ ubr1Δ cells proceeded at a 
rate similar to that in the single ubr1Δ mutant 
(Fig. 2C, lanes 22-25, and Fig. 2E). Thus, a 
double-mutant background that nearly 
completely stabilizes the wild-type rat 
MLSrAANAT3f must be naa30Δ ubr1Δ in that 
it should also lack the activity of the cognate 
NatC Nt-acetylase (Fig. 2C, lanes 18-21, and 
Fig. 2E). In agreement with this conclusion, 
the ablation of NAA10, encoding the non-
cognate NatA Nt-acetylase, did not have a 
synergistic effect on the rate of 
MLSrAANAT3f degradation in double-mutant 
naa10Δ ubr1Δ cells (Fig. 2C, lanes 22-25, 
and Fig. 2E). 
Previous work has identified the ER 
membrane-embedded E3 Ub ligase Doa10 as 
one Ac/N-recognin of the S. cerevisiae 
Ac/N-end rule pathway (39,59). We found 
that the degradation of the wild-type rat 
MLSrAANAT3f (t1/2 < 5 min in wild-type S. 
cerevisiae) was not significantly impaired in 
doa10Δ cells, in comparison to wild-type 
cells (Fig. 3D and F). We did not examine, so 
far, the other yeast Ac/N-recognin, Not4 (see 
the Introduction), for its possible role in 
targeting the Nt-acetylated rat 
Ac-MLSrAANAT3f in S. cerevisiae. We also 
don’t know, thus far, whether Teb4, the 
mammalian counterpart of the yeast Doa10 
N-recognin (60), is involved in the 
degradation of rat MLSrAANAT3f in a 
homologous (mammalian) setting. 
Degradation of Rat AANAT Is 
Proteasome-Dependent and Does Not 
Require Lys-8 – The demonstrated 
degradation of two forms of the wild-type rat 
MLSrAANAT3f (Ac-
MLSrAANAT3f and its 
non-Nt-acetylated counterpart) by the two 
branches of the N-end rule pathway (Fig. 2) 
already implied the proteasome dependency 
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of this degradation, given the known 
organization of the N-end rule pathway 
(Fig. 1A, B). To verify this in S. cerevisiae 
by independent means, CHX-chases with rat 
MLSrAANAT3f were carried out in wild-type 
vs. pdr5Δ cells in either the presence or 
absence of the MG132 proteasome inhibitor. 
(Cells lacking the transmembrane transporter 
PDR5 are more sensitive to MG132 (86,87).) 
As expected, given the proteasome 
dependence of the N-end rule pathway 
(Fig. 1A, B), the normally rapid degradation 
of the wild-type rat MLSrAANAT3f was 
substantially inhibited in wild-type 
S. cerevisiae in the presence of 50 μM 
MG132 (Fig.4A and B). This degradation 
was inhibited even more strongly in mutant 
pdr5Δ cells under the same conditions, 
confirming the proteasome dependence of at 
least the bulk of MLSrAANAT3f degradation 
(Fig.4A and B). 
N-terminal regions of mammalian 
AANATs contain a highly conserved Lys 
residue (e.g., Lys-8 in rat AANAT and 
Lys-10 in human AANAT) that has been 
suggested as a potential ubiquitylation site 
and thus a determinant of AANAT’s degron 
(33,88-90). To address this possibility, 
CHX-chases were performed in S. cerevisiae 
with wild-type MLSrAANAT3ha and a mutant 
containing a Lys-8-Arg mutation 
(MLSrAANAAT3ha
K8R). Wild-type 
MLSrAANAT3ha and the mutant 
MLSrAANAAT3ha
K8R were degraded at similar 
rates, indicating that the conserved lysine at 
this position (Lys-8 in rat MLSrAANAT) is 
not, by itself, a significant determinant of 
MLSrAANAT stability (Fig.4C). 
Degradation of human AANAT in 
S. cerevisiae – Fig. 3A, lanes 6-9, and Fig. 
3B show the results of a CHX-chase, in 
wild-type yeast, with the 207-residue (not 
counting the tag) (M)SThAANAT3f , the 
wild-type human AANAT C-terminally 
tagged with a triple-FLAG epitope. 
Parentheses around the superscript’s 
N-terminal Met residue denote the fact that 
this Met is cotranslationally cleaved off by 
MetAPs. While human (M)SThAANAT3f  was 
relatively unstable in S. cerevisiae 
(t1/2 ≈ 30 min), it was much longer-lived 
(including its higher zero-time, pre-chase 
level) than the wild-type rat MLSrAANAT3f 
under the same conditions (Fig. 3A, B). 
As was also done with the wild-type 
rat MLSrAANAT3f (Fig. 2C), we characterized 
the degradation of wild-type human 
(M)SThAANAT3f in S. cerevisiae strains 
deficient in specific components of the N-end 
rule pathway. The N-terminal Ser-Thr 
sequence of wild-type human 
(M)SThAANAT3f (after the cotranslational 
removal of the initially present N-terminal 
Met) made it likely that (M)SThAANAT3f was 
cotranslationally Nt-acetylated in vivo 
(59,63). This modification of human 
(M)SThAANAT3f would make it a potential 
target for degradation by the Ac/N-end rule 
pathway (Fig. 1B). In contrast, the 
non-Nt-acetylated human (M)SThAANAT3f 
would not be expected to be recognized by 
either the Ac/N-end rule or the Arg/N-end 
rule pathway (Fig. 1A), in the latter case 
owing to the absence of both a destabilizing 
N-terminal residue and a bulky hydrophobic 
(Ф) second residue. (A Met-Ф N-terminal 
motif, containing a second-position 
Ф residue, can act as an N-degron recognized 
by the Arg/N-end rule pathway (60,91).)  
Indeed, the rate of degradation of 
human (M)SThAANAT3f in ubr1Δ S. 
cerevisiae, which lacked the Ubr1 
N-recognin and therefore lacked the 
Arg/N-end rule pathway (Fig. 1A), was 
similar to the rate of (M)SThAANAT3f 
degradation in wild-type cells (Fig. Fig. 3C, 
lanes 1-4 vs. lanes 9-12, Fig. 3D, lanes 2-5 
vs. lanes 14-17, and Fig. 3E and F). The rate 
of (M)SThAANAT3f degradation that was 
observed with wild-type S. cerevisiae was 
also not significantly changed in doa10Δ 
cells, which lacked one of two known Ac/N-
recognins of the Ac/N-end rule pathway (Fig. 
1B,Fig. 3D, lanes 10-13 vs. lanes 2-5, and 
Fig. 3F). Surprisingly, however, 
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(M)SThAANAT3f was strongly destabilized in 
naa10Δ cells, which lacked the cognate 
Nt-acetylase for the N-terminal Ser residue 
(59,62); similar results were obtained with 
double-mutant naa10Δ ubr1Δ cells (Fig. 3C-
F). 
Given the much faster degradation of 
(M)SThAANAT3f in the absence of Naa10 
(e.g., Fig. 3C, lanes 1-4 vs. lanes 5-8, and 
Fig. 3E), i.e., in cells that would be incapable 
of Nt-acetylating (M)SThAANAT3f, we also 
carried out CHX-chases, in wild-type 
S. cerevisiae, with (M)PThAANAT3f. In the 
latter mutant, the N-terminal Ser was 
replaced by the non-Nt-acetylatable Pro 
residue. In contrast to wild-type 
(M)SThAANAT3f in naa10Δ cells, in which the 
(non-Nt-acetylated) (M)SThAANAT became 
strikingly short-lived, the (non-Nt-
acetylatable) (M)PThAANAT mutant was 
found to be longer-lived, in wild-type cells, 
than the Nt-acetylatable wild-type 
(M)SThAANAT3f (Fig.4D and E ). These 
results indicated that the observed 
accelerated degradation of the wild-type 
human (M)SThAANAT in naa10Δ S. 
cerevisiae was not caused by the failure to 
Nt-acetylate (M)SThAANAT in the absence of 
the NatA Nt-acetylase.  
We do not understand the 
mechanistic cause of the (reproducibly 
observed) much faster degradation of human 
(M)SThAANAT in naa10Δ S. cerevisiae 
(Fig. 3C-F). One possibility, which remains 
to be examined, is the apparent inhibition of 
the yeast Hsp90 chaperone system (centered 
on the S. cerevisiae Hsc82/Hsp82 proteins) 
in naa10Δ cells (J.-H.O. and A.V., 
unpublished data). If human (M)SThAANAT 
expressed in wild-type S. cerevisiae is a 
protected (from degradation) client of the 
Hsc82/Hsp82 system, a failure of this 
protection in naa10Δ mutant cells would 
make (M)SThAANAT vulnerable to a currently 
unknown pathway of the Ub system that is 
distinct from the Arg/N-end rule pathway. (A 
proteolytic pathway in question would be 
distinct from the Arg/N-end rule pathway 
because (M)SThAANAT was equally short-
lived in single-mutant naa10Δ and 
double-mutant naa10Δ ubr1Δ cells (Fig. 
3C-F).) In sum, the above Hsp90-based 
mechanism (which remains to be addressed 
in the context of the (M)SThAANAT protein) 
might underlie the strongly accelerated 
degradation of (M)SThAANAT in naa10Δ 
S. cerevisiae. 
Degradation of Rat AANAT in 
Human HEK293T Cells – To compare the 
relative rates of degradation of N-terminal 
mutants of rat AANAT in human HEK293T 
cells, the wild-type rat MLSrAANAT3f and its 
mutants (M)SMLSrAANAT3f, 
(M)SIrAANAT3f, 
and (M)PLSrAANAT3f (see items i-iv at the 
beginning of Results) were expressed in 
these cells using transient transfection. 
Preliminary experiments with wild-type 
MLSrAANAT3f encoded by a pcDNA3-based 
plasmid and expressed from the full-strength 
PCMV promoter indicated that the levels of 
expression of MLSrAANAT3f were high 
enough to saturate or near-saturate pathways 
that targeted MLSrAANAT3f for degradation 
in HEK293T cells. Specifically, at those 
(high) levels of expression, wild-type rat 
MLSrAANAT3f was either stable or was 
degraded slowly (data not shown). 
We addressed this problem by 
constructing a set of truncated derivatives of 
the original PCMV promoter, aiming to 
attenuate its activity. The resulting nested set 
of truncated promoters, denoted as PCMVt1, 
PCMVt2, and PCMVt3, comprised progressively 
shortened versions of the original PCMV. 
These truncations (Fig. 5A ) were similar 
(though not identical) to a series of PCMV 
truncations described earlier by Promega Inc. 
(92). Each of the PCMVt1, PCMVt2, and PCMVt3 
promoter variants was cloned into pcDNA3, 
replacing full-length PCMV. 
The wild-type rat MLSrAANAT3f was 
cloned into each of the above pcDNA3-based 
plasmids, and CHX chases were performed 
in HEK293T cells transiently-transfected 
with these constructs. Expression of 
MLSrAANAT3f from the PCMVt1 and PCMVt2 
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promoters reduced time-zero levels of 
MLSrAANAT3f  (measured by 
immunoblotting at the beginning of 
CHX-chase) by ~70% and by ~97%, 
respectively, in comparison to the 
unmodified PCMV promoter (Fig.5A-C ). With 
the most truncated promoter, PCMVt3, no 
MLSrAANAT3f could be detected at the same 
level of immunoblotting sensitivity (data not 
shown). The lower levels of MLSrAANAT3f 
expression that have been attained through 
the use of the PCMVt1 and PCMVt2 promoters 
resulted in a strongly increased rate of the 
posttranslational degradation of 
MLSrAANAT3f (t1/2 < 2 h vs. t1/2 > 8 h when 
MLSrAANAT3f was expressed from the full-
length PCMV promoter; Fig.5A-C). Treatment 
of HEK293T cells with the proteasome 
inhibitor MG132 during the chase increased 
the levels of MLSrAANAT3f expressed from 
these promoters, thereby confirming that in 
each case the bulk of degradation was 
proteasome-dependent (Fig.5A-C). The 
pcDNA3CMVt1 plasmid, which contained 
PCMVt1, one weakened version of the PCMV 
promoter, was chosen for experiments with 
HEK293T cells in this study. 
In agreement with the relative 
metabolic stabilities of AANAT proteins 
expressed in S. cerevisiae (Fig. 1A, B), the 
mutant rat (M)SIrAANAT3f, bearing a deletion 
of the Leu residue at position 2 of wild-type 
MLSrAANAT3f (Fig. 2A), was the 
longest-lived protein in the set of rat 
AANAT mutants examined in HEK293T 
cells (t1/2 > 4 h; Fig. 6A, lanes 12-16, and 
Fig. 6C). The wild-type rat MLSrAANAT3f 
and its (M)SMLSrAANAT3f mutant (see items 
i and ii at the beginning of Results) were 
significantly shorter-lived in HEK293T cells 
than  (M)SIrAANAT3f, with t1/2 ≈ 1 h and 
t1/2 < 1 h, respectively, versus t1/2 > 4 h 
(Fig. 6A, lanes 2-11, and Fig. 6C). 
We expected, a priori, that 
(M)SMLSrAANAT3f would initiate from the 
first encoded Met residue, particularly 
because of the inclusion of the Kozak 
“optimal” upstream sequence in the relevant 
plasmids used for expression of test AANAT 
proteins. We could verify that expectation 
through chase-degradation assays using an 
affinity-purified antibody against the 
Nt-acetylated N-terminus of MLSrAANAT3f  
(Fig. 5D). We produced and purified this 
antibody as described in Experimental 
Procedures. As shown in Fig. 5D, 
immunoblotting of SDS-PAGE-fractionated 
samples containing MLSrAANAT3f or 
(M)SMLSrAANAT3f with the anti-Ac-
 
MLSrAANAT antibody generated a positive 
signal only in samples expressing 
MLSrAANAT3f. If a construct expressing 
(M)SMLSrAANAT3f initiated translation (to a 
significant extent) from the second Met 
residue, the resulting translated protein 
would have been be MLSrAANAT3f. 
However, no signal was detected (using the 
above anti-Ac- MLSrAANAT antibody) with 
samples containing (M)SMLSrAANAT3f (Fig. 
5D), indicating negligible levels of 
translation initiation at the position-2 Met.  
Although the mutant (M)PLSrAANAT3f 
was partially stabilized relative to wild-type 
MLSrAANAT3f, the former protein was still 
significantly shorter-lived (t1/2 ≈ 2 h) than the 
most stable (M)SIrAANAT3f mutant (Fig. 6A, 
lanes 17-21, and Fig. 6C). While N-terminal 
Pro is not Nt-acetylated (59,63) (this makes 
N-terminal Pro-bearing proteins invulnerable 
to the Ac/N-end rule pathway), the 
N-terminal Pro residue might still be 
(weakly) recognized by the Arg/N-end rule 
pathway in some sequence contexts. 
Specifically, our SPOT-type, peptide-based 
binding assays (93) suggested that the Ubr1 
N-recognin of the S. cerevisiae Arg/N-end 
rule pathway (and, by inference, mammalian 
Ubr1 and Ubr2 as well) may weakly bind to 
N-terminal Pro when this residue is followed 
by a hydrophobic residue (J.-H. O., B.W. and 
AV., unpublished data). Thus, one 
interpretation of the “residual” instability of 
the rat (M)PLSrAANAT3f mutant (in 
comparison to the longest-lived 
(M)SIrAANAT3f mutant) is that the 
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(non-Nt-acetylated) N-terminal sequence 
Pro-Leu of (M)PLSrAANAT3f is weakly 
targeted by the Arg/N-end rule pathway, in 
contrast to the absence of targeting of the 
N-terminal Ser-Ile sequence of the 
(M)SIrAANAT3f mutant (Fig. 6A and C; see 
also Fig. 2B and D). 
As mentioned above, we found that 
transient transfection-based expression of 
AANAT from the full-strength PCMV 
promoter could be high enough to result in 
saturation or near-saturation of the relevant 
proteolytic pathways. While the use of the 
considerably weaker PCMVt1 promoter at least 
partially solved this problem (see above), 
additional studies would be required to make 
sure that pathway-saturation effects were 
consistently negligible with longer-lived 
AANAT derivatives that were expressed 
from PCMVt1. That said, the preponderance of 
our data makes it nearly certain that the 
observed differences in time-zero (before-
chase) levels of AANAT proteins were 
caused largely by differences in the rates of 
their degradation. 
The Bulk of Degradation of Rat 
AANAT Is Mediated by Polyubiquitylation of 
Its Lys residue(s)  – An earlier study, in 
which the wild-type rat MLSrAANAT was 
apparently not stabilized by conversion of its 
Lys residues to Arg, was based on 
measurements of steady-state levels of 
MLSrAANAT in HEK293 cells that had been 
treated or left untreated with the proteasome 
inhibitor MG132 (37). To address this issue 
more directly, we generated a 
triple-HA-tagged mutant, denoted 
MLSrAANAAT3ha
Kzero, of the wild-type rat 
MLSrAANAT in which all four of its Lys 
residues were converted to Arg. (A 
FLAG-based epitope tag could not be 
employed in these experiments, because 
FLAG contains a Lys residue that could 
potentially serve as a target for 
polyubiquitylation.)  
CHX chases in HEK293T cells 
(performed as described above) with the 
wild-type MLSrAANAT3ha versus its lysine-
lacking MLSrAANAAT3ha
Kzeromutant indicated 
that MLSrAANAAT3ha
Kzerowas nearly 
completely stable during the chase 
(t1/2 >> 4 h), whereas the wild-type 
MLSrAANAT3ha was degraded, with t1/2 ≈ 2 h 
(Fig. 6B and D). A treatment with MG132 
during CHX-chase strongly stabilized the 
wild-type MLSrAANAT3ha, confirming that its 
degradation is proteasome-dependent (Figure 
6B, left panel, lanes 2 and 6, and Fig. 6D). In 
contrast, the MG132 treatment during CHX-
chase of the lysine-lacking 
MLSrAANAAT3ha
Kzero mutant produced at most 
a marginal stabilizing effect, suggesting that 
even if there is a small (residual) amount of 
lysine-independent degradation of 
MLSrAANAAT3ha
Kzero, such a degradation 
would still require the proteasome (Figure 
6B, left panel, lanes 7 and 11, and Fig. 6D). 
In a different approach to the same 
problem, HEK293T cells were transiently-
transfected with the pcDNA3 vector or with 
plasmids expressing either MLSrAANAT3ha or 
MLSrAANAAT3ha
Kzero. Cells were then treated 
for 6 h with either MG132 or an equivalent 
volume of DMSO (in which the stock 
solution of MG132 was made). Thereafter 
cell extracts were immunoprecipitated with 
anti-HA magnetic beads, and the 
immunoprecipitates were fractionated by 
SDS-PAGE, followed by immunoblotting 
with anti-HA and anti-ubiquitin antibodies. 
Polyubiquitin chains (apparently linked to 
MLSrAANAT3ha) could be readily detected in 
fractionated immunoprecipitates of extracts 
from cells that expressed MLSrAANAT3ha 
(but, crucially, not from cells that expressed 
an empty vector), and the levels of 
polyubiquitin chains were significantly 
increased in the presence of MG132 (Fig. 6F, 
lanes 1-4). In contrast, significantly lower 
amounts of polyubiquitin chains were 
observed in fractionated immunoprecipitates 
of extracts from cells that expressed the 
lysine-lacking MLSrAANAAT3ha
Kzero (Fig. 6F, 
lane 5). Moreover, the presence of MG132 
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did not increase the low levels of detected 
polyubiquitin chains (Fig. 6F, lane 5 vs. lane 
6). The latter result suggested that (residual) 
polyubiquitin chains observed in cells that 
expressed MLSrAANAAT3ha
Kzero may be of a 
kind (e.g., (94)) that do not contribute to the 
proteasome-dependent degradation of 
MLSrAANAAT3ha
Kzero. In agreement with this 
interpretation, the lysine-lacking 
MLSrAANAAT3ha
Kzero mutant was expressed at 
significantly higher steady-state levels than 
the wild-type rat MLSrAANAT3ha in the 
absence of MG132 (in DMSO-treated cells) 
(Fig. 6E, lower panel), suggesting that the 
absence of Lys residues stabilized 
MLSrAANAAT3ha
Kzero against degradation 
throughout life histories of 
MLSrAANAAT3ha
Kzero molecules, including, 
possibly, their degradation during or 
immediately after their synthesis. 
Degradation of Human AANAT in 
Human HEK293T Cells – Degradation of the 
wild-type human (M)SThAANAT3f and its 
N-terminal Pro residue-bearing mutant 
(M)PThAANAT3f (see items vi and vii at the 
beginning of Results) were examined by 
CHX-chases in HEK293T cells. In 
agreement with the findings in S. cerevisiae 
(Figs. 2 and 3), the wild-type human 
(M)SThAANAT was longer-lived than the 
wild-type rat MLSrAANAT3f in HEK293T 
cells (compare Fig. 7A with Fig. 6A). 
Interestingly, the mutant human 
(M)PThAANAT3f was less stable than the 
wild-type human MLSrAANAT3f  during the 
course of a 2 h chase in HEK293T cells 
(Fig. 7A and C). 
We also asked whether the (relatively 
slow) degradation of the wild-type human 
(M)SThAANAT3f (Fig. 7A and C) required 
both its lysine-dependent ubiquitylation and 
the proteasome. CHX-chases were carried 
out with (M)SThAANAT3ha and its lysine-
lacking mutant (M)SThAANAAT3ha
Kzero. The 
latter protein was stable during the chase 
(t1/2 >> 4 h), whereas wild-type 
(M)SThAANAT3ha exhibited a weak but 
observable instability (Fig. 7B and D). 
Treatment with the MG132 proteasome 
inhibitor increased the level of the wild-type 
human (M)SThAANAT3ha during CHX-chase, 
confirming proteasome dependence of its 
(slow) degradation (Fig. 7B, lanes 3 and 7, 
and Fig. 7D). 
 
Discussion 
The ~23-kDa AANAT 
(arylalkylamine N-acetyltransferase, also 
called serotonin N-acetyltransferase) is 
apparently universal among animals, and is 
present in plants as well. AANAT converts 
the neurotransmitter serotonin to 
N-acetylserotonin (NAS), a regulatory 
compound in its own right and the immediate 
precursor of melatonin, a circulating 
hormone that regulates sleep and other 
circadian processes in vertebrates. The levels 
of melatonin and NAS are modulated by 
oscillatory circadian circuits and also impact 
those circuits, in addition to other effects of 
these compounds (see the Introduction). 
Hence the importance of temporal control of 
the AANAT enzyme. The expression of 
AANAT is regulated through both 
transcriptional and posttranslational 
mechanisms. Details of these mechanisms 
differ among vertebrates. In addition, 
although AANAT enzymes from different 
species are highly sequelogous (similar in 
sequence (71)) throughout their ORFs, the 
sequences of the first ~10 residues of 
ANAATs tend to differ even among 
relatively closely related mammals, let alone 
other animals (Fig. 1C). This pattern of 
variation suggests a blend of adaptive 
(function-linked, natural selection-based) 
changes in N-terminal sequences of 
AANATs versus an unknown (extent-wise) 
but apparently strong flux of quasi-neutral, 
drift-mediated changes of these N-terminal 
sequences on evolutionary timescales. 
In the present study, we approached 
the proteolysis-based regulation of rat and 
human AANATs (Fig. 1C) by expressing 
them and their mutants not only in 
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mammalian cells but also in the yeast 
S. cerevisiae. This strategy made possible the 
use of yeast genetics to illuminate specific 
proteolytic pathways involved, in parallel 
with experiments in mammalian cells. 
We found that the wild-type rat 
AANAT (MLSrAANAT) is targeted for 
degradation by two complementary branches 
of the N-end rule pathway. Specifically, we 
showed that the Nt-acetylated Ac-
MLSrAANAT is destroyed through the 
recognition of its Nt-acetylated N-terminal 
Met residue by the Ac/N-end rule pathway, 
whereas the non-Nt-acetylated MLSrAANAT 
is targeted for degradation by the Arg/N-end 
rule pathway, which recognizes the 
unacetylated N-terminal Met-Leu sequence 
of MLSrAANAT.  
The N-terminal sequence of the wild-
type human (M)SThAANAT ((Met)-Ser-Thr) 
is different from the Met-Leu-Ser sequence 
of rat MLSrAANAT (Fig. 1C). We found that 
the wild-type human (M)SThAANAT is 
considerably longer-lived than its rat 
MLSrAANAT counterpart, and does not 
appear to be an efficacious N-end rule 
substrate. Together, these and related results 
(Figs. 2-7) indicated both a major 
involvement of the N-end rule pathway in the 
control of rodent (specifically rat) AANAT 
and substantial differences in the regulation 
of rodent and human AANATs that stem 
from differences in their N-terminal 
sequences. 
The observed co-targeting of the two 
“complementary” forms of the rat 
MLSrAANAT by the two “complementary” 
branches of the N-end rule pathway (Figs. 2 
and 3) is in agreement with the earlier 
finding that the N-terminal region of 
MLSrAANAT, and specifically its Leu-2 
residue, are an important determinant of the 
observed metabolic instability of this 
AANAT (37). The cited study also suggested 
that either the Lys residues of MLSrAANAT 
or its surface-exposed Cys residues were not 
essential for its proteasome-mediated 
degradation (37). In the present work, we 
compared the degradation of wild-type 
MLSrAANAT and its lysine-lacking 
MLSrAANAAT3ha
Kzero mutant using 
cycloheximide (CHX) chases. Our results 
showed that the C-terminally 
triple-HA-tagged MLSrAANAAT3ha
Kzero mutant 
was completely stabilized in human 
HEK293T cells, in contrast to instability of 
wild-type MLSrAANAT, indicating that at 
least some Lys residues of MLSrAANAT were 
required for its degradation (Fig. 6B and D). 
A possible explanation of the above 
discrepancy stems from different choices of 
C-terminal epitope tags in the earlier and the 
present study. Specifically, Huang et al. (37) 
employed MLSrAANAT C-terminally tagged 
with c-Myc epitope (EQKLISEEDL), which 
contains a Lys residue. In the present work, 
we used a triple-HA tag, which lacks Lys 
residues (the sequence of single HA is 
YPYDVPDYA). Previous analyses of 
N-degrons have shown that the targeting 
apparatus of the Arg/N-end rule pathway 
selects a substrate’s internal lysine as a 
polyubiquitylation site through a process in 
which different (spatially competing, 
conformationally mobile) Lys residues can 
be chosen stochastically, depending on their 
ability to become transiently close to the 
substrate-bound E2-E3 complex (41,51,95). 
Thus, the presence of a Lys residue in the 
C-terminal c-Myc epitope of the earlier study 
(37) might have rendered the otherwise 
lysine-lacking MLSrAANAT mutant still 
targetable by the N-end rule pathway. Indeed 
and tellingly, our initial experiments with 
lysine-lacking mutants of MLSrAANAT have 
employed, inadvertently, a lysine-containing 
C-terminal FLAG tag, instead of the lysine-
lacking HA tag. Remarkably, the otherwise 
lysine-lacking but FLAG-tagged 
MLSrAANAAT3f
Kzero mutant was found to be 
unstable (Fig. 6B, right panel, and Fig. 7E), 
in contrast to the actually (completely) 
lysine-lacking, HA-tagged 
MLSrAANAAT3ha
Kzero mutant (Fig. 6B, left 
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panel and Fig. 6D), in agreement with the 
above tag-based explanation. 
In addition to polyubiquitylation and 
degradation, AANAT is also regulated 
through a site-specific phosphorylation, a 
modification that stimulates the binding of 
AANAT to at least one of the 14-3-3 
chaperone-like proteins (they are encoded by 
a family of several 14-3-3 genes in 
mammals). This interaction with 14-3-3 both 
protects (phosphorylated) AANAT from 
degradation and enhances its catalytic 
activity. Rat, human and other AANATs 
contain two previously mapped 
phosphorylation sites, Thr-29 and Ser-203 
(numbers refer to the sequence of rat 
MLSrAANAT). Phosphorylation at Thr-29 is 
conserved in all examined mammalian 
AANATs (31). This phosphorylation, by 
protein kinase A (PKA) and/or by protein 
kinase C (PKC), augments the interaction 
between AANAT and 14-3-3 both in vitro 
and in vivo (1,5,37). By expressing AANATs 
not only in mammalian cells but also in the 
heterologous setting of S. cerevisiae, we 
could analyze the degradation of AANATs in 
the possible absence of phosphorylation at 
Thr-29 (or its equivalent) and also in the 
possible absence of AANAT interactions 
with 14-3-3 proteins. While S. cerevisiae has 
two 14-3-3 proteins (96), there is no 
evidence, so far, that bears on their binding, 
in vivo, to a mammalian AANAT. 
Our attempts to observe a 
phosphorylation-induced in vivo binding of 
the wild-type rat MLSrAANAT either to an 
endogenous yeast 14-3-3 protein or to the 
(overexpressed) human 14-3-3ζ protein were 
unsuccessful so far, despite a variety of tried 
approaches (B.W. and A.V., unpublished 
data). Nevertheless, the likely conceptual 
benefit of achieving a phosphorylation-
inducible interaction between a mammalian 
AANAT and a specific 14-3-3 protein, in a 
setting of greatly reduced complexity of 
14-3-3s (in comparison to the large set of 
their mammalian counterparts), justifies 
further work in this direction. 14-3-3 proteins 
are abundant, broadly expressed, 
multifunctional chaperone-like proteins that 
modulate catalytic activities of enzymes to 
which 14-3-3s bind, and also regulate 
protein-protein interactions and subcellular 
targeting of specific proteins (97-99). It is 
possible, indeed likely, that 14-3-3 proteins 
may bind, in a regulated manner, not only to, 
for example, rat MLSrAANAT but to other 
N-end rule substrates as well, thereby 
controlling the rates of degradation of such 
substrates in ways that remain to be explored. 
Recently, the naturally occurring 
mutant human protein RGS2Q2L was shown 
to be a conditionally short-lived substrate of 
both the Ac/N-end rule pathway and the 
Arg/N-end rule pathway (60). This clinically-
relevant mutant of RGS2 (a negative 
regulator of specific G proteins) was 
identified in a cohort of hypertensive 
Japanese patients (100) (see also the 
Introduction). In the present study, we 
demonstrated that the otherwise unrelated rat 
MLSrAANAT protein, whose N-terminal 
Met-Leu sequence is identical to that of 
RGS2Q2L, is also targeted for degradation by 
both branches of the N-end rule pathway 
(Figs. 1 and 2). These results further 
expanded the set of identified mammalian 
N-end rule substrates of the Met- type. 
Interestingly, RGS2, an N-end rule 
substrate (60), has been identified as a 
physiologically relevant inhibitor of the 
AANAT-dependent melatonin production 
(101). Light-stimulated, norepinephrine-
induced increases in the levels and activity of 
AANAT are mediated by G-protein-coupled 
adrenergic receptors, whose activation 
increases intracellular cAMP, and 
subsequently the levels of AANAT as well, 
at least in part through an increased 
phosphorylation of AANAT and the resulting 
induction of its binding to protective 14-3-3 
proteins (5,28). While acting to increase the 
levels and activity of AANAT (which is 
required for the synthesis of NAS and 
melatonin), cAMP also acts as a negative-
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feedback inhibitor of melatonin production 
through up-regulation of Rgs2 transcription. 
The resulting increase in RGS2 inhibits the 
activity of G proteins that are coupled to the 
norepinephrine-responsive receptor, a 
negative-feedback circuit that acts to 
decrease cAMP levels (101). AANAT results 
of the present study, together with the earlier 
evidence that RGS2 is both a conditionally 
short-lived N-end rule substrate and an 
(indirect) down-regulator of AANAT 
(60,101), indicate that the N-end rule 
pathway is a pleiotropic controller of circuits 
that either directly or indirectly modulate 
AANAT.  
Previous studies of AANAT 
demonstrated that its transcriptional 
regulation can be different in different 
species, but it has been conjectured that 
mechanisms and regulation of AANAT 
degradation would be more conserved in 
evolution (11,34-36). As shown in the 
present study, the rates of degradation of the 
human and rat AANAT proteins are quite 
different. Moreover, whereas rat 
MLSrAANAT is destroyed by the N-end rule 
pathway (Figs. 2 and 6), human 
(M)SThAANAT is substantially resistant to 
this pathway (Figs. 3 and 7). Nevertheless, if 
the identification of RGS2 as a feedback 
inhibitor of AANAT expression in the rat 
pineal gland (101) could also be shown to 
extend to human RGS2, the N-end rule 
pathway would be a regulator of AANAT in 
humans as well, albeit an indirect one. 
An earlier study of human 
(M)SThAANAT described its apparent 
degradation by the proteasome, but did not 
detect its ubiquitylation (33). In that study, 
the instability of human (M)SThAANAT was 
inferred from increases in its steady-state 
levels in the presence of a proteasome 
inhibitor. In the present work, we employed, 
in particular, CHX-chases to show that while 
human (M)SThAANAT is degraded by the 
proteasome, it is substantially longer-lived 
than rat MLSrAANAT under the same 
conditions, either in mammalian cells or in 
S. cerevisiae (Figs. 2-7).  
In sum, our results indicate both a 
major involvement of the N-end rule 
pathway in the control of rodent AANATs 
and substantial differences in the regulation 
of rodent and human AANATs that stem 
from differences in their N-terminal regions 
(Fig. 1C). What is the cause of the 
remarkable variability of N-terminal 
sequences of AANATs during mammalian 
(and, more generally, animal) evolution? 
Given the extent of variability (Fig. 1C), it is 
nearly certain that a substantial fraction of 
these changes resulted from a quasi-neutral, 
unselected genetic drift (102). At the same 
time, the broad and biologically relevant 
variation in detailed circadian rhythms 
among different animal species (owing to 
specific ecological and physiological 
adaptations) and the role of AANAT in these 
rhythms suggest that the seeming 
randomness of AANATs’ N-terminal 
sequences (Fig. 1C) may be obscuring, so 
far, a set of adaptive (selected) changes in 
these sequences over evolutionary 
timescales.  
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Figure Legends 
 
FIGURE 1. The mammalian N-end rule pathway and N-terminal regions of 
AANAT enzymes. See the Introduction for references and descriptions of pathway’s 
mechanisms and biological functions. Amino acid residues are denoted by single-letter 
abbreviations. A, the mammalian Arg/N-end rule pathway. It targets proteins for degradation 
through their specific unacetylated N-terminal residues. A yellow oval denotes the rest of a protein 
substrate. “Primary”, “secondary”, and “tertiary” refer to mechanistically distinct classes of 
destabilizing N-terminal residues. Ntan1 and Ntaq1 are N-terminal amidases (Nt-amidases) that 
convert, respectively, the tertiary destabilizing N-terminal residues Asn and Gln to Asp and Glu. 
The Ate1 arginyltransferase (R-transferase) conjugates Arg, a primary destabilizing residue, to 
N-terminal Asp, Glu and (oxidized) Cys. “Type 1” and “type 2” refer, respectively, to two sets of 
primary destabilizing N-terminal residues, basic (Arg, Lys, His) and bulky hydrophobic (Leu, Phe, 
Trp, Tyr, Ile, and Met, if the latter is followed by a bulky hydrophobic residue (Ф)). These sets of 
N-terminal residues are recognized by two distinct substrate-binding sites of N-recognins, the 
pathway’s E3 ubiquitin ligases, whose (possibly incomplete) list includes Ubr1, Ubr2, Ubr4, and 
Ubr5. B, the mammalian Ac/N-end rule pathway. It targets proteins through their Nα-terminally 
acetylated (Nt-acetylated) residues. Red arrow on the left indicates the cotranslational removal of 
the N-terminal Met residue by Met-aminopeptidases (MetAPs). N-terminal Met is retained if a 
residue at position 2 is larger than Val. C, the first 10 amino acid residues of animal AANAT 
enzymes, in vertebrates and an invertebrate such as Drosophila melanogaster. See the 
Introduction for descriptions of AANATs. 
 
FIGURE 2. The wild-type rat MLSrAANAT as a substrate of both branches of 
the N-end rule pathway. A, the wild-type rat MLSrAANAT and its mutants that were 
constructed and analyzed in the present study. Amino acid residues are denoted by single-letter 
abbreviations. The Leu (L) residue, at position 2 in wild-type MLSrAANAT, is highlighted in red to 
make it easier to follow sequence alterations in specific mutants. B, immunoblotting with antibody 
to actin was used as a loading control. Lane 1, fluorescently labeled molecular mass markers 
(Li-Cor); their masses, in kDa, are indicated on the left. Lane 2, wild-type S. cerevisiae were 
transformed with vector (V) alone (control). Cycloheximide (CHX)-chases were performed at 
30°C for the indicated times in wild-type S. cerevisiae with the wild-type rat MLSrAANAT3f (lanes 
3-6), and with its mutants (M)SMLSrAANAT3f (lanes 7-10), 
(M)SIrAANAT3f (lanes 11-14), and 
(M)PLSrAANAT3f (lanes 15-18). The bands of AANAT3f and actin are indicated on the right. 
C, immunoblotting with antibody to tubulin was used as a loading control. Lane 1, 37 kDa and 
50 kDa molecular mass markers (see lane 1 in B). CHX-chases with the wild-type rat 
MLSrAANAT3f in wild-type S. cerevisiae (lanes 2-5) and its mutants naa30Δ (lanes 6-9), naa10Δ 
(lanes 10-13), ubr1Δ (lanes 14-17), naa30Δ ubr1Δ (lanes 18-21), and naa10Δ ubr1Δ (lanes 
22-25). The bands of MLSrAANAT3f and tubulin are indicated on the left. D, quantification of data 
in B. E, quantification of data in C. All quantified CHX-chase assays were carried out at least three 
times and yielded results within 10% of the data shown. 
 
FIGURE 3. Degradation assays with the wild-type human (M)SThAANAT in 
S. cerevisiae. A, Comparison of degradation rates of the wild-type rat MLSrAANAT3f and the 
wild-type human (M)SThAANAT3f in S. cerevisiae. Immunoblotting with antibody to actin was 
used as a loading control. Lane 1, wild-type S. cerevisiae were transformed with vector (V) alone 
(control). CHX-chases were performed at 30°C for the indicated times in wild-type S. cerevisiae 
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with the wild-type rat MLSrAANAT3f (lanes 2-5) and with the wild-type human 
(M)SThAANAT3f 
(lanes 6-9). The bands of AANAT and actin are indicated on the left. B, quantification of data in 
A. C, CHX-chases with the wild-type human (M)SThAANAT3f in wild-type S. cerevisiae (lanes 1-4) 
and its mutants naa10Δ (lanes 5-8), ubr1Δ (lanes 9-12), and naa10Δ ubr1Δ (lanes 13-16). The 
bands of human (M)SThAANAT3f and actin are indicated on the left. D, Lane 1, wild-type 
S. cerevisiae were transformed with vector (V) alone (control). CHX-chases with the wild-type 
human (M)SThAANAT3f in wild-type S. cerevisiae (lanes 2-5) and its mutants naa10Δ (lanes 6-9), 
doa10Δ (lanes 10-13), and ubr1Δ (lanes 14-17). The bands of human (M)SThAANAT3f and actin 
are indicated on the left. E, quantification of data in C. F, quantification of data in D. All 
quantified CHX-chase assays were carried out at least three times and yielded results within 10% 
of the data shown. 
 
FIGURE 4. Degradation assays with a proteasome inhibitor and AANAT 
mutants in S. cerevisiae. A, Lane 1, wild-type S. cerevisiae were transformed with vector (V) 
alone (control). Lanes 2-5, CHX-chase was performed at 30°C for the indicated times in wild-type 
S. cerevisiae with the wild-type rat MLSrAANAT3ha. Lanes 6-9, same as in lanes 2-5 but the 
CHX-chase was in the presence of the MG132 proteasome inhibitor (see Experimental 
Procedures). Lanes 10-13, same as in lanes 2-5 but in pdr5Δ S. cerevisiae lacking the efflux pump 
Pdr5. Lanes 14-17, same as in lanes 10-13 but in the presence of MG132. The bands of actin and 
MLSrAANAT3ha are indicated on the left. B, quantification of data in A. C, CHX-chases were 
performed in wild-type S. cerevisiae with the wild-type rat MLSrAANAT3ha (lanes 2-5) and with its 
Lys-8-to-Arg mutant MLSrAANAAT3ha
K8R (see Results). The bands of tubulin and AANAT are 
indicated on the left. An asterisk on the right denotes a band of protein that crossreacted with 
anti-ha antibody (the band is also present in lane 1, the vector-only control). D, Lane 1, wild-type 
S. cerevisiae were transformed with vector (V) alone (control). Lanes 2-5, CHX-chase was 
performed at 30°C for the indicated times in wild-type S. cerevisiae with the wild-type human 
(M)SThAANAT3f. Lanes 6-9, same as in lanes 2-5 but with the mutant human 
(M)PThAANAT3f. The 
bands of actin and AANAT are indicated on the left. E, quantification of data in A. All quantified 
CHX-chase assays were carried out at least three times and yielded results within 10% of the data 
shown. 
 
FIGURE 5. Weakened derivatives of the PCMV promoter in HEK293T cells, and 
degradation assays using antibody to Nt-acetylated rat MLSrAANAT. A, a simplified 
diagram of the “wild-type” (unmodified) PCMV promoter in the cloning vector, with schematically 
illustrated binding sites for the NFκB, SP1 and CREB transcriptional regulators. Two 5’-terminal 
truncations of wild-type PCMV, denoted as PCMVt1 and PCMVt2, are also indicated. B, Lane 1, 
HEK293T cells were transformed with vector (V) alone (control). CHX-chases were performed at 
37°C for the indicated times in HEK293T cells with the wild-type rat MLSrAANAT3f expressed 
either from the unmodified PCMV promoter (lanes 2-5), or from the PCMVt1 promoter (lanes 7-10), or 
from the PCMVt2 promoter (lanes 12-15). Lanes 6, 10, and 16, same as lanes 5, 9, and 15, except 
that the MG132 proteasome inhibitor was present during 8-h CHX-chases, in each case (see 
Experimental Procedures and Results). The bands of tubulin and MLSrAANAT3f are indicated on 
the left. C, quantification of data in B. Symbols shown separately and framed in black squares 
correspond to altered (increased) levels of test proteins in the presence of MG132. All quantified 
CHX-chase assays were carried out at least three times and yielded results within 10% of the data 
shown. (D) Immunoblotting with affinity-purified antibody to Nt-acetylated MLSrAANAT (see 
Experimental Procedures). Lane 1, HEK293T cells were transformed with vector (V) alone 
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(control) bearing the (weakened) PCMVt1 promoter. CHX-chases were performed at 30°C for the 
indicated times in HEK293T cells with the wild-type rat MLSrAANAT3f (lanes 2-5) and its mutant 
(M)SMLSrAANAT3f (lanes 7-10). Lanes 6 and 11, same as lanes 5 and 10 except that the MG132 
proteasome inhibitor was present during 4-h CHX-chases, in each case (see Experimental 
Procedures). The bands of rAANAT and tubulin (the latter a loading control) are indicated on the 
left.  
 
FIGURE 6. Degradation and ubiquitylation assays with rat and human 
AANATs in human HEK293T cells. A, Lane 1, HEK293T cells were transformed with vector 
(V) alone (control) bearing the (weakened) PCMVt1 promoter (see Results and Fig. 5A-C). 
Immunoblotting with antibody to tubulin was used as a loading control. CHX-chases were 
performed at 37°C for the indicated times in HEK293T cells with the wild-type rat MLSrAANAT3f 
(lanes 2-5), and with its mutants (M)SMLSrAANAT3f (lanes 7-10), 
(M)SIrAANAT3f (lanes 12-15), and 
(M)PLSrAANAT3f (lanes 17-20). Lanes 6, 11, 16, and 21, same as lanes 5, 10, 15, and 20 except that 
the MG132 proteasome inhibitor was present during a 4-h CHX-chase, in each case (see 
Experimental Procedures). The bands of AANAT3f and tubulin are indicated on the right. An 
asterisk on the left denotes a band of protein that crossreacted with anti-flag antibody (the band is 
also present in lane 1, the vector-only control). B, left panel: Lane 1, the same as the control in 
lane 1 of A. CHX-chases were performed at 37°C for the indicated times in HEK293T cells with 
the wild-type rat MLSrAANAT3ha (lanes 2-5) and with its lysine-lacking mutant 
MLSrAANAAT3ha
Kzero(lanes 7-10). Lanes 6 and 11, same as lanes 5 and 10 except that MG132 was 
present during a 4-h CHX-chase, in each case. Right panel: the same as in the left panel, but both 
the wild-type MLSrAANAT3f and its lysine-lacking counterpart were C-terminally tagged with a 
triple flag tag, which contains a Lys residue, in contrast to the HA tag, which lacks lysines (see 
Results and Discussion). C, quantification of data in A. D, quantification of data in B. Symbols 
shown separately and framed in black squares or rectangles correspond to altered levels of test 
proteins in the presence of MG132. All quantified CHX-chase assays were carried out at least 
three times and yielded results within 10% of the data shown. E, immunoblot analyses, using anti-
Ub antibody, of total, input (before immunoprecipitation) extracts from HEK293T cells that had 
been transfected either with vector alone (lanes 1 and 2), or with plasmid expressing the wild-type 
rat MLSrAANAT3ha (lanes 3 and 4), or with plasmid expressing its lysine-lacking counterpart 
MLSrAANAAT3ha
Kzero(lanes 5 and 6). The MG132 proteasome inhibitor was either omitted (lanes 1, 3 
and 5) or added to HEK293T cells (to the final concentration of 10 μM) 6 h before preparation of 
extracts (lanes 2, 4, and 6). The lower panel shows the results of detecting non-ubiquitylated 
MLSrAANAT3ha (absent in the control lanes 1 and 2) with anti-ha antibody. F, same as in E, but 
immunoblot analyses (using anti-Ub antibody) of the input samples after their 
immunoprecipitation with anti-ha antibody (followed by SDS-PAGE), to isolate and detect 
ubiquitylated AANAT3ha species. 
 
FIGURE 7. Degradation of the wild-type human (M)SThAANAT and its mutants 
in human HEK293T cells. The test proteins were expressed in HEK293T cells using a plasmid 
bearing the (weakened) PCMVt1 promoter (see Results and Fig. S3). A, Lane 1, fluorescently labeled 
molecular mass markers (Li-Cor), with their masses, in kDa, indicated on the left. CHX-chases 
were performed at 37°C for the indicated times in HEK293T cells with the wild-type human 
(M)SThAANAT3f (lanes 2-5) and with its mutant 
(M)PThAANAT3f (lanes 6-9). B, Lane 1, 
fluorescently labeled molecular mass markers, with their masses, in kDa, indicated on the left. 
Lane 2, HEK293T cells were transformed with vector (V) alone (control). CHX-chases were 
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performed at 37°C for the indicated times in HEK293T cells with the wild-type human 
(M)SThAANAT3ha (lanes 3-6) and with its lysine-lacking mutant 
(M)SThAANAAT3ha
Kzero (lanes 8-11). 
Lanes 7 and 12, same as lanes 6 and 11, except that the MG132 proteasome inhibitor was present 
during a 4-h CHX-chase, in each case (see Experimental Procedures). The bands of actin and 
AANAT are indicated on the right. Asterisks on the right in A and B denote a protein band 
(possibly the same protein and possibly a derivative of AANAT) that reacted with both anti-flag 
antibody in A and anti-ha antibody in B. C, quantification of data in A. D, quantification of data 
in B. E, quantification of data in Fig. 6B, right panel, similarly to the analogous quantifications 
described in the legend to Fig. 6C and D. All quantified CHX-chase assays were carried out at 
least three times and yielded results within 10% of the data shown. 
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Table 1. S. cerevisiae strains used in this study. 
Strains Relevant genotypes Sources 
BY4742 MATα his3-1 leu2-0 lys2-0 ura3-0 can1-100 Open Biosystems. 
BY15470 naa30Δ::kanMX6 in BY4742 Open Biosystems 
BY10976 naa10Δ::KanMX6 in BY4742  Open Biosystems 
BY17299 doa10Δ:KanMX6 in BY4742 Open Biosystems 
CHY345 ubr1Δ::LEU2 in BY4742 (91) 
CHY346 ubr1Δ::LEU2 doa10Δ:KanMX6 in BY4742 This study 
BWY29 naa10Δ::kanMX6 ubr1Δ::LEU2 in BY4742 This study 
CHY349 naa30Δ::kanMX6 ubr1Δ::LEU2 in BY4742 (40) 
JOY487 naa30Δ::natNT2 in BY4742 This study 
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Table 2. Plasmids used in this study. 
Plasmid Description Source or Reference 
pcDNA3 
 
Invitrogen 
pCISII-
rAANAT rAANAT in pCISII (78) 
pRS313Cup1 pRS313 containing the PCUP1 promoter Varshavsky Lab Collection 
pRS416Gal1 pRS416 containing the PGAL1 promoter Varshavsky Lab Collection 
pBW105 MLSrAANAT3f in pRS416 with PGal1 This study 
pBW106 (M)SIrAANAT3f in pRS416 with PGal1 This study 
pBW107 (M)SMLSrAANAT3f in pRS416 with PGal1 This study 
pBW135 MLSrAANAT3ha in pRS313 with PCup1 This study 
pBW173 pcDNA3(PCMVt1) This study 
pBW206 MLSrAANAT3f in pcDNA3(PCMVt1) This study 
pBW209 (M)PLSrAANAT3f in pRS416 with PGal1 This study 
pBW211 (M)SMLSrAANAT3f in pcDNA3(PCMVt1) This study 
pBW212 (M)SIrAANAT3f in pcDNA3(PCMVt1) This study 
pBW213 (M)PLSrAANAT3f in pcDNA3(PCMVt1) This study 
pBW394 MLSrAANAAT3ha
K8R in pRS416 with PGal1 This study 
pBW395 (M)SThAANAT3f in pRS416 with PGal1 This study 
pBW419 (M)PThAANAT3f in pRS416 with PGal1 This study 
pBW466 (M)SThAANAT3f in pcDNA3(PCMVt1) This study 
pBW467 (M)PThAANAT3f in pcDNA3(PCMVt1) This study 
pBW477 MLSrAANAT3ha in pcDNA3(PCMVt1) This study 
pBW478 MLSrAANAAT3ha
Kzero in pcDNA3(PCMVt1) This study 
pBW481 (M)SThAANAT3f in pcDNA3(PCMVt1) This study 
pBW482 (M)SThAANAAT3ha
Kzero in pcDNA3(PCMVt1) This study 
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Table 3. PCR primers used in this study. 
Primer Sequence 
BW239 5'-CCTTGAATTCATACCCATGTTGAGCATCCA-3' 
BW240 5'-CCTTGAATTCATACCCATGAGCATCCA-3' 
BW241 5'-CCTTGAATTCATACCCATGAGCATGTTGAGCA-3' 
BW243 5'-CCTTTCCTTGTAGTCGGATCCACCGCAGCCACTGTT-3' 
BW244 5'-CCTTAAGCTTACTTGTCATCGTCGTCCTTGTAGTCGG-3' 
BW335 5'-TTGAATTCATGTTGAGCATCCACCCC-3' 
BW338 5'-GTATGGGTAGCAGCCACTGTTCC-3' 
BW339 5'-CAGTGGCTGCTACCCATACGATG-3' 
BW340 5'-TTCTCGAGTCAAGCGTAATCTGGAACGTC-3' 
BW352 5'-AATTGAATTCACCATGTTGAGCATCC-3' 
BW353 5'-AATTGAATTCACCATGAGCATCCACC-3' 
BW354 5'-AATTGAATTCACCATGAGCATGTTGA-3' 
BW355 5'-AATTCTCGAGTTACTTGTCATCGTCG-3' 
BW375 5'-TTAATCTAGATGCATGCTCGAGC-3' 
BW376 5'-CGTTAATCGCGACCAAAATCAACGGGACTTTC-3' 
BW412 5'-TTGAATTCATGCCCTTGAGCATCCACCCC-3' 
BW705 5'-TTGAATTCATACCCATGTCCACGCAGAGCACCCACCCCCTGAAACCTGA 
    GGCCCCACGTCTGCCACCTGGGATC-3' 
BW711 5'-CTTATAGTCACCAGAACCAGAGCAGCCGCTGTTCCTGCGCAGG-3' 
BW712 5'-CAGGAACAGCGGCTGCTCTGGTTCTGGTGACTATAAGGATG-3' 
BW771 5'-TTGAATTCATACCCATGCCAACGCAGAGCACCCACCCCCTGAAACCTG 
    AGGCCCCACGTCTGCCACCTGGGATC-3' 
BW784 5'-CTGAGTAAGTCTCTCTCTGTCCCAAAGTGAACC-3' 
BW785 5'-GGTTCACTTTGGGACAGAGAGAGACTTACTCAG-3' 
BW786 5'-CAGCAGGACGGAGCCTCTGCCCTGCTGCCGGAAG-3' 
BW787 5'-CTTCCGGCAGCAGGGCAGAGGCTCCGTCCTGCTG-3' 
BW788 5'-GGCCTGGAAACCAAATCTCTCATAGAAGGGCAC-3' 
BW789 5'-GTGCCCTTCTATGAGAGATTTGGTTTCCAGGCC-3' 
BW866 5'-TTGAATTCACCATGTCCACGCAGAGCACCCACCCCC-3' 
BW867 5'-TTGAATTCACCATGTCCACGCAGAGCACCCACCCCCTGAGACCTGA 
    GGC-3' 
BW868 5'-TTGAATTCACCATGCCAACGCAGAGCACCCACCCC-3' 
BW884 5'-TTAAGAATTCACCATGTCCACGCAGAGCACC-3' 
BW885 5'-GTCAGGAACATCGTATGGGTAGCAGCCGCTGTTCCTGCGCAGG-3' 
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